RESUMEN

UNLABELLED: The case of a 66 year-old female - the oldest known living patient with Niemann-Pick disease type C (NP-C) who remains free of any neurological or psychiatric manifestations 18 years after presentation - is presented. An incidental finding of massive splenomegaly was detected during a routine pelvic ultrasound. The pathology report after splenectomy showed the presence of lipid-laden macrophages. Fibroblasts cultured in LDL-enriched medium revealed abnormal filipin staining consistent with cholesterol-filled vesicles and the rate of cholesterol esterification in response to stimulation of LDL-cholesterol uptake was significantly depressed at 6% of that seen in cells from normal controls, but at a level similar to that observed in an NP-C positive control. Molecular genetic testing later revealed a compound heterozygous mutant NP-C genotype comprising two previously described disease-causing mutations in the NPC1 gene, one in exon 8 (c.1133T>C [V378A]) and one in exon 13 (c.1990G>A [V664M]). These findings confirmed the diagnosis of NP-C. Only three patients with this disorder aged > 53 years have previously been reported, all of whom presented with neurological or neuropsychiatric manifestations. Our patient is the first reported NP-C patient, now in her seventh decade of life, who has to date only manifested splenomegaly. This case highlights the extreme clinical variability of NP-C, and the need to consider this disease in the differential diagnosis of organomegaly, even in the absence of neurological, psychiatric and related clinical signs. SYNOPSIS: An elderly female patient with confirmed NP-C and isolated splenomegaly has remained asymptomatic for neurological, cognitive, psychiatric or ophthalmologic abnormailities into her seventh decade of life.

RESUMEN

Glutaric acidemia type 1 (GA1) is overrepresented in the aboriginal population of Island Lake, Manitoba, and northwestern Ontario who speak the Ojibway-Cree (Oji-Cree) dialect. The carrier frequency in these communities has been predicted to be as high as 1 in 10 individuals. Prior to beginning newborn screening for GA1 in May 1998, 18 of 20 affected patients diagnosed at this center have been from these high-risk communities. Most have followed an acute encephalopathic course with permanent neurologic sequelae and high mortality. They excrete small amounts of glutaric acid and 3-hydroxyglutaric acid and have significant residual enzyme activity. A single homozygous mutation in glutaryl-CoA-dehydrogenase (GCDH IVS-1 + 5g right arrow t) has been identified in this population. DNA-based newborn screening targeted to our high-risk communities was begun in order to provide presymptomatic detection and treatment of affected patients. Of the first 1176 newborns screened, 4 affected infants were identified and treated with a low-protein diet, carnitine, and riboflavin. All 4 infants have required numerous hospitalizations for treatment of intercurrent illnesses. Eventually, 3 infants presented with acute dystonic encephalopathy and seizures along with permanent neurological sequelae. One of these infants died unexpectedly at home at 18 months of age. The fourth, now 9 months old, has had a gastrostomy tube placed to facilitate fluid replacement in addition to a standard treatment protocol and is doing well. The reasons for our initial disappointing outcomes in the first 3 of 4 affected babies are likely multiple. Based on our early experience and that of other centers screening newborns for GA1, current therapeutic strategies may be insufficient in preventing the occurrence of neurologic sequelae in some children. An incomplete understanding of the neurotoxic mechanisms underlying this devastating disorder hampers effective management.

Asunto(s)

Glutaratos/sangre , Mutación , Tamizaje Neonatal , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Oxidorreductasas/deficiencia , Oxidorreductasas/genética , Canadá , Femenino , Pruebas Genéticas , Glutaril-CoA Deshidrogenasa , Humanos , Lactante , Recién Nacido , Masculino

RESUMEN

The spectrum of clinical presentation of fatty acid oxidation defects (FAOD) continues to expand. One FAOD, L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency has been associated with liver disease in pregnancies involving a heterozygous mother carrying an affected fetus. Hepatic carnitine palmitoyltransferase (CPT I) deficiency typically presents as a Reyelike syndrome in children between 8 and 18 mo. of age. We have investigated a family in which the mother developed liver disease consistent with acute fatty liver of pregnancy (AFLP) and hyperemesis gravidarum in her two successive pregnancies. Neither child nor their mother was found to carry the common LCHAD G1528C mutation. Both children were subsequently shown to have absent activity of CPT I. This is the first report of CPT I deficiency presenting as maternal illness in pregnancy.

Asunto(s)

Hígado Graso/enzimología , Errores Innatos del Metabolismo Lipídico/complicaciones , Hígado/enzimología , Complicaciones del Embarazo/enzimología , Adulto , Carnitina O-Palmitoiltransferasa/deficiencia , Carnitina O-Palmitoiltransferasa/metabolismo , Hígado Graso/complicaciones , Femenino , Enfermedades Fetales/enzimología , Enfermedades Fetales/genética , Enfermedades Fetales/metabolismo , Humanos , Errores Innatos del Metabolismo Lipídico/enzimología , Errores Innatos del Metabolismo Lipídico/genética , Embarazo , Tercer Trimestre del Embarazo

RESUMEN

We report that measurement of whole-blood palmitate oxidation is a rapid and inexpensive screening test for fatty acid oxidation defects. The assay has been adapted from published assays using cultured fibroblasts or isolated white blood cells. Micro whole-blood samples are incubated with tritiated palmitic acid as substrate. The tritiated water produced is proportional to the mitochondrial beta-oxidation of palmitic acid. Patients with confirmed beta-oxidation defects show low whole-blood palmitate oxidation.

Asunto(s)

Ácidos Grasos/metabolismo , Errores Innatos del Metabolismo Lipídico/diagnóstico , Ácido Palmítico/sangre , Adolescente , Células Cultivadas , Femenino , Fibroblastos/metabolismo , Humanos , Lactante , Recién Nacido , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo Lipídico/metabolismo , Masculino , Oxidación-Reducción , Estudios Retrospectivos

RESUMEN

PURPOSE: To describe the clinical and biologic features of neuroblastoma (NB) in two siblings and their maternal second cousin. PATIENTS AND METHODS: NB was diagnosed in the siblings at 2 1/2 (patient 2) and 5 (patient 3) years of age. NB was diagnosed in their maternal second cousin (patient 1) when she was 7 years old. Standard clinical and biological data, tumor karyotype, and tumor allelotype at select loci were obtained. RESULTS: Patient 1 had International Neuroblastoma Staging System (INSS) stage 4 NB and unfavorable histology but no evidence of MYCN amplification; she died from complications of autologous bone marrow transplantation in second remission. Patient 2 had INSS stage 4 NB with unfavorable histology but no MYCN amplification; her disease recurred 39 months after completing therapy. Patient 3 had INSS stage 1 NB with favorable biologic features; he was treated with surgical excision and remains free of disease. CONCLUSIONS: Familial NB may occur at a later age than predicted by the tumor suppressor gene model of inherited cancer. This report further emphasizes the clinical and biological heterogeneity of familial NB.

Asunto(s)

Neuroblastoma , Edad de Inicio , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Femenino , Genes myc , Marcadores Genéticos , Humanos , Masculino , Neuroblastoma/diagnóstico , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/genética , Neuroblastoma/fisiopatología , Linaje

RESUMEN

Aspartylglucosaminuria (AGU) is a lysosomal storage disease caused by deficiency of aspartylglucosaminidase. The disease is overrepresented in the Finnish population, in which one missense mutation (Cys163Ser) is responsible for 98% of the disease alleles. The few non-Finnish cases of AGU which have been analyzed at molecular level have revealed a spectrum of different mutations. Here, we report two new missense mutations causing AGU in two Canadian siblings. The patients were compound heterozygotes with a G299-->A transition causing a Gly100-->Gln substitution and a T404-->C transition resulting in a Phe135-->Ser change in the cDNA coding for aspartylglucosaminidase. The younger patient recently underwent bone marrow transplantation.

Asunto(s)

Acetilglucosamina/análogos & derivados , Aspartilglucosaminuria , Aspartilglucosilaminasa/genética , Trasplante de Médula Ósea/métodos , Enfermedades por Almacenamiento Lisosomal/genética , Mutación Puntual , Acetilglucosamina/orina , Canadá , Femenino , Humanos , Recién Nacido , Enfermedades por Almacenamiento Lisosomal/terapia , Enfermedades por Almacenamiento Lisosomal/orina , Linaje , Análisis de Secuencia de ADN

Asunto(s)

Mutación , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Oxidorreductasas/deficiencia , Oxidorreductasas/genética , Secuencia de Aminoácidos , Pueblo Asiatico , Secuencia de Bases , Glutaril-CoA Deshidrogenasa , Humanos , Datos de Secuencia Molecular , Ontario , Empalme del ARN , Análisis de Secuencia de ADN

RESUMEN

We have discovered a single homoallelic nucleotide substitution as the putative cause of the perinatal (lethal) form of hypophosphatasia in Canadian Mennonites. Previous linkage and haplotype analysis in this population suggested that a single mutational event was responsible for this autosomal recessive form of hypophosphatasia. The mutation is a guanosine-to-adenosine substitution at nucleotide position 1177 in exon 10 of the tissue nonspecific (liver/bone/kidney) alkaline phosphatase gene. This Gly317-->Asp mutation segregates exclusively with the heterozygote phenotype we previously assigned by biochemical testing (maximum combined lod score of 18.24 at theta = 0.00). This putative disease-causing mutation has not been described in controls nor in other non-Mennonite probands with both lethal and nonlethal forms of hypophosphatasia studied to date. This Gly317-->Asp mutation changes a polar glycine to an acidic aspartate at amino acid position 317 within the highly conserved active site region of the 507-amino-acid polypeptide. Carrier screening for this lethal mutation in our high-risk population is now feasible.

Asunto(s)

Fosfatasa Alcalina/genética , Genes Letales , Genes Recesivos , Genes , Hipofosfatasia/genética , Isoenzimas/genética , Mutación Puntual , Fosfatasa Alcalina/deficiencia , Alelos , Secuencia de Bases , Estudios de Cohortes , Análisis Mutacional de ADN , ADN Complementario/genética , Etnicidad/genética , Femenino , Frecuencia de los Genes , Haplotipos/genética , Heterocigoto , Humanos , Hipofosfatasia/epidemiología , Hipofosfatasia/etnología , Recién Nacido , Isoenzimas/deficiencia , Escala de Lod , Masculino , Manitoba/epidemiología , Datos de Secuencia Molecular , Ontario/epidemiología

RESUMEN

We describe two brothers with 5,10-methylene tetrahydrofolate reductase (MTHFR) deficiency. The younger patient first developed limb weakness, incoordination, paresthesiae, and memory lapses at age 15 years, and by his early twenties he was wheelchair bound. His older brother remains asymptomatic at age 37 years. Both had homocystinuria and homocystinemia and low plasma levels of methionine. MTHFR activities in cultured skin fibroblasts of both patients were < 10% control and residual enzyme activities were markedly reduced on heating. The parents had intermediate enzyme activities and the reductase in the father (who had unexplained paraparesis and homocystinemia), but not in the mother, was also thermolabile. Both patients were treated with oral folate and betaine which improved, but did not totally correct, their biochemical abnormality. MTHFR deficiency should be considered in the differential diagnosis of unexplained neurologic disease in adolescents and adults.

Asunto(s)

Errores Innatos del Metabolismo/genética , Enfermedades del Sistema Nervioso/genética , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/deficiencia , Adulto , Betaína/uso terapéutico , Estabilidad de Enzimas , Ácido Fólico/uso terapéutico , Homocistina/metabolismo , Humanos , Masculino , Errores Innatos del Metabolismo/tratamiento farmacológico , Errores Innatos del Metabolismo/metabolismo , Metionina/sangre , Metilenotetrahidrofolato Reductasa (NADPH2) , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades del Sistema Nervioso/metabolismo , Paraparesia Espástica Tropical/tratamiento farmacológico , Paraparesia Espástica Tropical/genética , Paraparesia Espástica Tropical/metabolismo

RESUMEN

We describe hepatic carnitine palmitoyltransferase (CPT I) deficiency in three children (a brother and sister and their second cousin) from an extended inbred Hutterite kindred. The patients were first seen between 8 and 18 months of age with recurrent episodes of hypoketotic hypoglycemia accompanied by a decreased level of consciousness and hepatomegaly. One patient had two Reye syndrome-like episodes. Abnormal organic acids were rarely detected in urine. Serum total and free carnitine levels were elevated in all three patients. Fibroblast acyl-coenzyme A dehydrogenase activities were normal in all, but palmitic acid oxidation, performed in fibroblasts from one patient, was less than 10% of control values. Activity of CPT I in cultured skin fibroblasts from the three patients was 10% to 15% of control levels; CPT II activity was normal. Activity of CPT I and CPT II in muscle from one patient was normal. Atypical features in two of these patients were greatly elevated levels of liver enzymes and creatine kinase during acute episodes. The patients have recently been successfully treated with medium-chain triglycerides and avoidance of fasting. Early identification and treatment of this disorder may avert potentially fatal episodes of hypoglycemia.

Asunto(s)

Carnitina O-Palmitoiltransferasa/deficiencia , Hígado/enzimología , Carnitina O-Palmitoiltransferasa/metabolismo , Ácido Graso Desaturasas/metabolismo , Femenino , Fibroblastos/enzimología , Fibroblastos/metabolismo , Humanos , Lactante , Masculino , Músculos/enzimología , Linaje , Religión

RESUMEN

Cultured interleukin 2 (IL-2)-dependent leukocytes from 13 patients with glutaric aciduria type I, 12 obligate carriers, 105 family members and 31 normal controls were assayed for glutaryl-CoA dehydrogenase activity. Of the 13 affected patients, 10 (all Ojibway Indian) had residual enzyme activity (2-13% of control) and 3 patients (all non-Indian) had undetectable enzyme activity. There was partial overlap between the distribution of enzyme activity in obligate heterozygotes and in normal controls (mean values +/- SD: 6.29 +/- 0.94 and 10.75 +/- 2.58 nmol/h per mg protein respectively). Using an arbitrary cutoff level of < 7 nmol/h per mg protein as presumptive evidence of carrier status, the observed frequency of carriers did not differ significantly from that expected from their a priori risk of carrier status. Thirteen per cent of the family members had inconclusive status (activity between 7 and 8.5 nmol/h per mg protein). The method appears suitable for carrier detection, although definitive carrier assignment awaits identification of the mutation(s) responsible for glutaric aciduria type I.

Asunto(s)

Errores Innatos del Metabolismo de los Aminoácidos/genética , Glutaratos/metabolismo , Heterocigoto , Interleucina-2/metabolismo , Linfocitos/metabolismo , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Errores Innatos del Metabolismo de los Aminoácidos/orina , Células Cultivadas , Glutaril-CoA Deshidrogenasa , Humanos , Indígenas Norteamericanos , Oxidorreductasas/deficiencia

Asunto(s)

Acetilglucosamina/análogos & derivados , Errores Innatos del Metabolismo de los Aminoácidos/orina , Acetilglucosamina/orina , Errores Innatos del Metabolismo de los Aminoácidos/genética , Errores Innatos del Metabolismo de los Aminoácidos/patología , Femenino , Hepatomegalia/patología , Humanos , Recién Nacido , Esplenomegalia/patología

RESUMEN

We have diagnosed type I glutaric aciduria (GA-I) in 14 children from 7 Old Order Amish families in Lancaster County, Pennsylvania. An otherwise rare disorder, GA-I appears to be a common cause of acute encephalopathy and cerebral palsy among the Amish. The natural history of the disease, which was previously unrecognized in this population, is remarkably variable and ranges from acute infantile encephalopathy and sudden death to static extrapyramidal cerebral palsy to normal adult. Ten patients first manifested the disease between 3 and 18 months at the time of an acute infectious illness. Four of these children died in early childhood, also during acute illnesses. However, there has been little progression of the neurological disease after age 5 years in the surviving children and intellect usually has been preserved, even in children with severe spastic paralysis. When well, patients have plasma glutaric acid concentrations ranging from 4.8 to 14.2 mumol/liter (nl 0-5.6 mumol/liter) and urinary glutaric acid concentrations from 12.5 to 196 mg/g creatinine (nl 0.5-8.4 mg/g creatinine). We have found that GA-I can be diagnosed in the Amish by measurement of urinary glutaric acid concentrations using isotope-dilution gas chromatography/mass spectrometry, whereas the diagnosis can easily be missed by routine urine organic acid gas chromatography.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Errores Innatos del Metabolismo de los Aminoácidos/etnología , Parálisis Cerebral/etiología , Glutaratos/orina , Espasticidad Muscular/etiología , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Parálisis/etiología , Enfermedad Aguda , Adolescente , Adulto , Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Células Cultivadas , Niño , Preescolar , Femenino , Cromatografía de Gases y Espectrometría de Masas , Glutaratos/sangre , Glutaratos/metabolismo , Glutaril-CoA Deshidrogenasa , Humanos , Lactante , Recién Nacido , Masculino , Oxidorreductasas/deficiencia , Linaje , Pennsylvania

RESUMEN

OBJECTIVE: To compare the prevalence of hereditary metabolic diseases in the native and non-native populations of Manitoba and northwestern Ontario. DESIGN: Retrospective analysis. SETTING: Children's Hospital, Winnipeg. PATIENTS: Patients were selected by three methods: laboratory tests designed to screen patients suspected of having a metabolic disease, laboratory investigation of newborn infants with abnormalities detected through screening, and investigation of near relatives of probands with disease. RESULTS: A total of 138 patients with organic acid, amino acid and carbohydrate disorders were seen from 1960 to 1990. Of these, 49 (36%) were native Indians (Algonkian linguistic group). This was in sharp contrast to the proportion of native Indians in the total study population (5.8%). Congenital lactic acidosis due to pyruvate carboxylase deficiency (13 patients), glutaric aciduria type I (14 patients) and primary hyperoxaluria type II (8 patients) were the most common disorders detected. Other rare disorders included glutaric aciduria type II (one patient), 2-hydroxyglutaric aciduria (one patient) and sarcosinemia (one patient). Underreporting, especially of glutaric aciduria type I and hyperoxaluria type II, was likely in the native population. CONCLUSIONS: Hereditary metabolic diseases are greatly overrepresented in the native population of Manitoba and northwestern Ontario. We recommend that native children who present with illnesses involving disturbances of acid-base balance or with neurologic, renal or liver disease of unknown cause by investigated for a possible metabolic disorder.

Asunto(s)

Acidosis Láctica/etnología , Errores Innatos del Metabolismo de los Aminoácidos , Errores Innatos del Metabolismo de los Aminoácidos/etnología , Errores Innatos del Metabolismo de los Carbohidratos/etnología , Indígenas Norteamericanos , Acidosis Láctica/epidemiología , Adolescente , Errores Innatos del Metabolismo de los Aminoácidos/epidemiología , Errores Innatos del Metabolismo de los Carbohidratos/epidemiología , Niño , Femenino , Glucosa-6-Fosfatasa/metabolismo , Humanos , Lactante , Recién Nacido , Masculino , Manitoba/epidemiología , Manitoba/etnología , Ontario/epidemiología , Ontario/etnología , Prevalencia

Asunto(s)

Hiperoxaluria Primaria/complicaciones , Cálculos Renales/etiología , Cálculos de la Vejiga Urinaria/etiología , Adolescente , Adulto , Oxidorreductasas de Alcohol/deficiencia , Deshidrogenasas de Carbohidratos/deficiencia , Niño , Preescolar , Femenino , Humanos , Hiperoxaluria Primaria/clasificación , Hiperoxaluria Primaria/enzimología , Lactante , Masculino

RESUMEN

Twenty obligate carriers of infantile hypophosphatasia (HOPS), a severe autosomal recessive metabolic bone disorder, were studied and compared with 36 controls. Decreased serum alkaline phosphatase activity and increased urinary phosphoethanolamine excretion were confirmed in the HOPS carriers. Relative hyperphosphatemia was documented for the first time in the carriers. Logistic regression analysis was used to develop models for the diagnosis of and screening for HOPS carriers in the high-risk population of Manitoba Mennonites. Models based on serum alkaline phosphatase activity and on serum phosphate levels with or without urinary phosphoethanolamine excretion were used for diagnostic purposes. A model based on serum alkaline phosphatase activity and on the serum phosphate level was the most suitable for screening.

Asunto(s)

Fosfatasa Alcalina/sangre , Biomarcadores/sangre , Etanolaminas/orina , Tamización de Portadores Genéticos , Hipofosfatasia/diagnóstico , Fosfatos/sangre , Adulto , Biomarcadores/orina , Calcio/sangre , Femenino , Humanos , Hipofosfatasia/genética , Recién Nacido , Masculino , Tamizaje Masivo , Valores de Referencia , Análisis de Regresión

RESUMEN

We measured plasma levels of pyridoxal-5'-phosphate (PLP), a cofactor form of vitamin B6 and apparent natural substrate for alkaline phosphatase (ALP), in carriers and in non-carriers of the severe perinatal and infantile forms of hypophosphatasia, both before and after an oral load of pyridoxine (i.e. 1/3 mg/kg body weight). The assignment of carrier status was determined by serum ALP activity, level of serum inorganic phosphate, and if necessary urinary phosphoethanolamine excretion. Plasma PLP levels were significantly increased in the carriers both before and especially after B6 loading.

Asunto(s)

Heterocigoto , Hipofosfatasia/sangre , Fosfato de Piridoxal/sangre , Piridoxina , Adulto , Femenino , Humanos , Hipofosfatasia/genética , Masculino , Persona de Mediana Edad , Estadística como Asunto

RESUMEN

In July 1983, the Manitoba Perinatal Screening Programme modified its existing procedure for neonatal screening for galactosemia by introducing quantitation of total galactose plus galactose-1-phosphate from dried blood spots using the Multistat centrifugal analyzer. The first 4 years of experience with this method in combination with the Beutler spot test for galactose-1-phosphate uridyl transferase activity is the subject of this report. Of 70,336 newborns screened, 142 (0.20%) met the criteria for clinical follow up. Of these, one child was confirmed to have classical galactosemia and nine children were found to be Duarte/galactosemia genetic compounds. This method of galactosemia screening has proven to be rapid, sensitive, efficient, and the method of choice for mass screening of disorders of galactose metabolism.

Asunto(s)

Galactosemias/epidemiología , Tamizaje Masivo/métodos , Galactosa/análisis , Galactosemias/diagnóstico , Galactosemias/genética , Galactosafosfatos/análisis , Humanos , Recién Nacido , Manitoba

RESUMEN

We report two brothers with a previously undescribed type of mitochondrial encephalomyopathy and associated aminoacidopathy. Both have growth failure, progressive intellectual decline, deafness, neurologic dysfunction, exercise intolerance, lactic acidosis, and abnormal plasma and cerebrospinal fluid amino acid levels (elevated levels of alanine and low levels of threonine, methionine, citrulline, tryptophan, ornithine, arginine, and lysine). A muscle biopsy specimen taken from the younger, more severely affected brother showed abnormal mitochondrial morphology. Activities of the following enzymes in cultured fibroblasts from both boys were normal: pyruvate dehydrogenase, pyruvate carboxylase, phosphoenolpyruvate carboxykinase, cytochrome oxidase, reduced nicotinamide-adenine dinucleotide-cytochrome c reductase, and succinate cytochrome c reductase. Fibroblast mitochondria from the younger boy showed undetectable (less than 1% of control values) adenosine triphosphate synthesis with pyruvate and malate, whereas adenosine triphosphate synthesis with succinate was 70% of control values. These data indicate probably deficient activity of complex I of the electron transport chain. The boys' mother has progressive neurosensory hearing loss; their sister is clinically normal. Both mother and sister have many of the biochemical abnormalities found in the boys. It is possible, but not proved, that this disorder is inherited through maternal mitochondria.

Asunto(s)

Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Mitocondrias/ultraestructura , Encefalopatías/complicaciones , Niño , Transporte de Electrón , Humanos , Masculino , Síndrome

RESUMEN

The continuous infusion of cytarabine, daunorubicin, and etoposide offers several theoretical advantages over bolus infusion in the treatment of acute nonlymphocytic leukemia. To date, this approach has been limited by the need for three separate iv lines. The in vitro stability and compatibility of these three agents were therefore evaluated. Solutions of 200 mg of cytarabine, 25 mg of daunorubicin, and 300 mg of etoposide per 750 ml of 5% dextrose and 0.45% saline were prepared alone and in combination. The solutions were evaluated visually, spectrophotometrically, and by high-pressure liquid chromatography (HPLC) twice daily for 72 hours. Precipitates or color changes were not noted. Changes in the patterns of the spectral scans and chromatographs were not observed. Concentrations of the drugs as assessed by HPLC were stable over the 72-hour period of observation for both individual and combined drug preparations. In conclusion, cytarabine, daunorubicin, and etoposide are stable and compatible in vitro for at least 72 hours. These drugs can therefore be administered together by continuous infusion using a single iv line.

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica , Citarabina , Daunorrubicina , Etopósido , Cromatografía Líquida de Alta Presión , Citarabina/administración & dosificación , Daunorrubicina/administración & dosificación , Interacciones Farmacológicas , Etopósido/administración & dosificación , Técnicas In Vitro , Espectrofotometría